Next-generation medium optimises CHO cell productivity

Thermo Fisher Scientific has launched Gibco™ Efficient-Pro™ Medium (+) Insulin, a next-generation medium designed to enhance protein production and streamline workflows for insulin-dependent CHO cell lines. The medium delivers up to 61% higher protein titres compared with alternatives while supporting high viable cell densities and robust growth without compromising product quality.

Efficient-Pro Medium (+) Insulin is compatible with a broad range of insulin-dependent CHO cell lines and comes in flexible packaging formats, including a dry media version using Advanced Granulation Technology™ (AGT™) for rapid reconstitution and scalability. Its animal origin–free (AOF) formulation reduces process variability and simplifies regulatory compliance, providing researchers and manufacturers with greater confidence in reproducible results.

Ideal for developers of monoclonal antibodies, bispecifics, and Fc-fusion proteins, the medium offers consistent growth and production conditions, reducing variability and supporting streamlined process development.

“Our Efficient-Pro Medium (+) Insulin addresses key industry challenges by combining AGT dry format with an AOF formulation,” said Sara Henneman, VP and GM of Thermo Fisher’s cell culture and cell therapy business. “It enables reliable, high-performance production while supporting the development of innovative therapies.”

As the biologics industry demands faster development timelines, lower costs, and greater supply chain agility, this medium eliminates the need for manual insulin supplementation and helps ensure consistent, high-quality bioprocessing.

“With this launch, we’re helping customers scale rapidly, adapt to evolving project needs, and accelerate the delivery of life-changing therapies,” added Andy Campbell, Senior Director of R&D at Thermo Fisher Scientific. 

More information online